RTOG Foundation, Inc.
Clinical Trials
162
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (157 trials with phase data)• Click on a phase to view related trials
Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment
- Conditions
- Intracranial Meningioma
- Interventions
- Drug: [177Lu]Lu-DOTATATEOther: Standard of Care treatments
- First Posted Date
- 2025-05-02
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- RTOG Foundation, Inc.
- Target Recruit Count
- 153
- Registration Number
- NCT06955169
A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2019-01-18
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- RTOG Foundation, Inc.
- Target Recruit Count
- 188
- Registration Number
- NCT03809000
- Locations
- 🇺🇸
Arizona Center for Cancer Care - Gilbert, Gilbert, Arizona, United States
🇺🇸Arizona Center for Cancer Care - Peoria, Peoria, Arizona, United States
🇺🇸Arizona Center for Cancer Care - Phoenix, Phoenix, Arizona, United States
Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma
- Conditions
- Glioblastoma MultiformeGliomaAstrocytoma
- Interventions
- First Posted Date
- 2018-10-26
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 712
- Registration Number
- NCT03722355
SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Interventions
- Radiation: Stereotactic Body Radiation Therapy (SBRT)
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- RTOG Foundation, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT03546582
- Locations
- 🇺🇸
University of Arizona Cancer Center - North Campus, Tucson, Arizona, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Cleveland Clinic - Weston, Weston, Florida, United States
Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2016-05-11
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- RTOG Foundation, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02768558
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸University of Florida, Gainesville, Florida, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 33
- Next